Patent ID: 6194163
Filing Date: 2001-02-27
Classification: C07K,G01N,Y10S

Abstract:
A method for quantitatively determining human acute phase serum amyloid A protein (A-SAA), A-SAA1 and/or A-SAA2, which comprisesa) contacting a sample of a biological fluid with antibody specific for the A-SAA (anti-A-SAA), wherein the anti-A-SAA is raised against recombinant A-SAA which is free from C-SAA and which is soluble under physiological conditions;b) contacting said sample with an organic solvent in an amount sufficient to unmask A-SAA epitopes prior to or simultaneous with the anti-A-SAA antibody contact; andc) determining the amount of the A-SAA present in the sample.